Corporate earnings forecasts for the second quarter were lowered so much that companies are easily beating them.Market Insiderread more
The central bank is not normally in the business of easing into an economy that is showing few signs of a recession, generally holding fire until more pronounced signs of a...The Fedread more
His case for gold comes as central banks get more aggressive with policies that devalue currencies and are about to cause a "paradigm shift" in investing.Marketsread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
House Speaker Nancy Pelosi says she wants her chamber to vote on a debt ceiling and budget deal by July 26.Politicsread more
Philips has acquired a start-up that texts you about your poop. That's Medumo, a Boston-based company, which works with hospitals to guide their patients through common...Technologyread more
The "'Cadillac tax," set to go into effect in 2022, is unpopular with both Republicans and Democrats, who say it punishes the middle class.Health and Scienceread more
Federal Judge William Pauley wrote in a court filing made public Wednesday that materials related to a campaign finance probe of Cohen should be unsealed — and denied a...Politicsread more
The U.S. economy continued growing at a "modest" rate in recent weeks, with consumers continuing to spend and a "generally positive" outlook overall even in the face of...Economyread more
CSX said it expects revenue to fall as much as 2% in 2019, well below a previous forecast of an increase of 1% to 2%.Marketsread more
Facebook's head of Calibra David Marcus is grilled during a House Financial Services Committee hearing over the company's digital currency plans.Technologyread more
Vertex Pharmaceuticals is expected to report data any day now on a combination of drugs to treat cystic fibrosis, a rare, inherited disease that causes the buildup of sticky mucus in the lungs and other areas and is often fatal by age 40.
Vertex's Kalydeco, approved in 2012, was the first medicine to address the underlying genetic cause of the disease, and is hailed as a huge breakthrough for patients. But it addresses mutations affecting just a fraction of CF patients worldwide. The new drug combination, which combines Kalydeco with Lumacaftor, would expand that population dramatically.
For that reason, analysts have called the data release one of the most important events for biotech investors of the year—not just for Vertex, but for sentiment across the sector. Kalydeco alone drew $371 million in 2013 revenue. Altogether, analysts expect Vertex's cystic fibrosis medicines—if successful—could draw more than $5 billion in revenue by 2018.
For more about the upcoming data, see the above video.
—By CNBC's Meg Tirrell